Harrow Health Inc
NASDAQ:HROW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Harrow Health Inc
NASDAQ:HROW
|
US |
|
G
|
Guangdong New Grand Long Packing Co Ltd
SZSE:002836
|
CN |
|
B
|
Blackstone Inc
SWB:BBN1
|
US |
|
X
|
Xinjiang East Universe Gas Co Ltd
SSE:603706
|
CN |
|
C
|
Chengdu Xuguang Electronics Co Ltd
SSE:600353
|
CN |
|
electroCore, Inc.
NASDAQ:ECOR
|
US |
|
LVMH Moet Hennessy Louis Vuitton SE
OTC:LVMHF
|
FR |
|
STX Heavy Industries Co Ltd
KRX:071970
|
KR |
Harrow Health Inc
Nestled within the bustling world of pharmaceutical innovation, Harrow Health Inc. emerges as a dynamic player with a distinctive business model tailored to transforming ophthalmic healthcare. With its roots planted firmly in the field of eye care, Harrow Health has mastered the art of compounding pharmaceuticals, focusing on delivering affordability and accessibility. The company operates primarily through its subsidiary, ImprimisRx, a compounding pharmacy that serves a robust network of ophthalmologists and optometrists across the United States. ImprimisRx’s unique approach involves creating custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings. By prioritizing the compounding of prescription medications in its expansive network of accredited pharmacies, Harrow Health crafts a niche in the high-demand ophthalmology sector.
Central to Harrow Health’s business strategy is its ability to capitalize on inefficiencies in the traditional drug market. By emphasizing a direct-to-prescriber model, the company circumvents many of the traditional barriers and costs associated with large pharmaceutical firms. This allows for a reduction in drug prices and improves distribution efficiency. Moreover, Harrow Health’s focus extends beyond compounding; it is actively involved in acquiring and licensing innovative ophthalmic technologies and products, constituting a broader ecosystem within eye care. This multi-pronged approach not only drives revenue through direct sales but also strengthens its position in the healthcare sector by investing in emerging therapies and expanding its reach in the marketplace. Such strategic maneuvers allow Harrow Health to sustain its growth trajectory while continuing to champion patient-centered care.
Nestled within the bustling world of pharmaceutical innovation, Harrow Health Inc. emerges as a dynamic player with a distinctive business model tailored to transforming ophthalmic healthcare. With its roots planted firmly in the field of eye care, Harrow Health has mastered the art of compounding pharmaceuticals, focusing on delivering affordability and accessibility. The company operates primarily through its subsidiary, ImprimisRx, a compounding pharmacy that serves a robust network of ophthalmologists and optometrists across the United States. ImprimisRx’s unique approach involves creating custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings. By prioritizing the compounding of prescription medications in its expansive network of accredited pharmacies, Harrow Health crafts a niche in the high-demand ophthalmology sector.
Central to Harrow Health’s business strategy is its ability to capitalize on inefficiencies in the traditional drug market. By emphasizing a direct-to-prescriber model, the company circumvents many of the traditional barriers and costs associated with large pharmaceutical firms. This allows for a reduction in drug prices and improves distribution efficiency. Moreover, Harrow Health’s focus extends beyond compounding; it is actively involved in acquiring and licensing innovative ophthalmic technologies and products, constituting a broader ecosystem within eye care. This multi-pronged approach not only drives revenue through direct sales but also strengthens its position in the healthcare sector by investing in emerging therapies and expanding its reach in the marketplace. Such strategic maneuvers allow Harrow Health to sustain its growth trajectory while continuing to champion patient-centered care.
Revenue: Harrow reported consolidated Q4 revenue of $89.1 million and full-year 2025 revenue of $272 million, up 33% and 36% year-over-year, respectively.
Profitability: Adjusted EBITDA was $24.2 million in Q4 and $61.9 million for the full year, a 54% year-over-year increase, showing operating leverage as revenue scales.
2026 Guidance: Full-year 2026 revenue guidance of $350 million to $365 million with $133 million–$153 million in H1 and $203 million–$226 million in H2; Adjusted EBITDA guidance $80 million to $100 million.
Commercial cadence / seasonality: Management expects a softer first half (stocking drawdown, deductible dynamics, ASC transition) with the majority of EBITDA and revenue acceleration in the second half of 2026.
Salesforce expansion: Company will more than double the Vevye sales force by Memorial Day and add roughly 100 sales roles in H1 to support Vevye, Triesence and upcoming launches.
Product momentum: Vevye showed accelerating prescriptions and payer coverage (covered patients averaged ~9 refills annually); IHEEZO posted strong traction (Q4 $35.9M; full year $81.3M) with a retina pivot and expected price improvements in H2; Triesence delivered its strongest quarter and the company plans to double its dedicated sales team.
Pipeline / M&A: Harrow expects an NDA submission for G-Melt in early 2027 and is advancing IHEEZO clinical evidence (investigator-initiated data at ASRS and a Harrow-sponsored Phase II readout by end of 2026).
